Navigation Links
Mayo Clinic to Pilot Collexis' Expert Profiling
Date:9/6/2007

Mayo Clinic joins the ranks of Johns Hopkins, University of California San Francisco, University of South Carolina and Others in Expert Profiling

COLUMBIA, S.C., Sept. 6 /PRNewswire-FirstCall/ -- Collexis (OTC Bulletin Board: CLXS.OB), leading developer of knowledge management (KM) and discovery software, has reached an agreement to launch its Expert Profiles System as a pilot project in collaboration with Mayo Clinic Libraries. It joins the ranks of distinguished Collexis clients including Johns Hopkins University, the University of California, San Francisco, the University of South Carolina, Merck & Co., Inc., Bristol-Myers Squibb, Lockheed Martin, the World Health Organization, the National Institutes of Health and the US Department of Defense.

J. Michael Homan, Director, Mayo Clinic Libraries, explained, "The ability of Collexis technology to review, retrieve and display knowledge concepts is simply not possible with standard relational or bibliographic database systems, and therefore holds great promise for database discovery that goes well beyond current methods. Collexis will provide a means to mine hidden knowledge in existing databases and documents. It also has the capability to bridge the gap not only between the patient-based clinical information systems (EMR) and the information in knowledge-based systems familiar to research libraries, but also often in their own silos."

The Collexis software creates profiles of text, for example, peer-reviewed literature, web pages, internal documents, e-mails, speech transcripts and grants. These profiles represent the key ideas or concepts in those texts and are presented in a format known as the Collexis Fingerprint. This enables data mining at a level that is much deeper and far more robust than traditional keyword searching. The resulting conceptual search system will provide the Mayo Clinic Libraries with a unique virtual knowledge directory.

Mr. Homan continued, "We are pleased to be able to offer the benefits of this innovative technology - to provide our researchers with tools that support discovery and collaboration, and contribute to improving patient care."

Bill Kirkland, Collexis CEO, commented, "For more than 100 years the Mayo Clinic Libraries has been dedicated to meeting the information needs of its community. It is therefore particularly gratifying to work in partnership with this prestigious institution as it moves towards knowledge discovery tools that utilize the power of semantic technology to find, share and integrate information more easily and effectively."

During the first phase of the Expert Profiles System proof of concept pilot, 10 years of publications authored by 250 of the more than 3,000 Mayo Clinic researchers and clinicians will be "fingerprinted." This semantic profiling process makes use of the structure of a particular field's professional terminology (fundamentally a thesaurus) and embodies the way people understand those terms and concepts. It minimizes superfluous information and allows users to mine data at an intuitive, non-language- specific level. The data extracted will help identify domain experts in specific biomedical disciplines.

The Mayo Clinic Libraries has also opted to utilize Mediator(TM), a SyynX application powered by Collexis. This intuitive software will enable users to search more than 16 million citations and abstracts in the life sciences and clinical medicine utilizing the Collexis Fingerprint and its patented semantic analysis.

The Expert Profiler System project is being carried out in concert with German-based Collexis Development Partner, SyynX Solutions.

Collexis Holdings, Inc.

Collexis Holdings, Inc., a global knowledge discovery company since 1999, is headquartered in Columbia, South Carolina (USA) with two subsidiaries; Collexis Inc. in Columbia, South Carolina, USA and Collexis, B.V. in Geldermalsen, The Netherlands. Collexis patented technology builds conceptual profiles of text, called Fingerprints, from documents, websites, e-mails and other digitized content and matches them with a comprehensive list of pre- defined "fingerprinted" concepts to make research results more relevant and efficient. This matching of concepts eliminates the ambiguity and lack of priority associated with word searches. The results are often described as "finding needles in many haystacks." Through this novel approach, Collexis can build unique applications to search, index, and aggregate information as well as prioritize, trend and predict data based on sources in multiple industries without the limitations of language or dialect. Representative clients include the NIH, Johns Hopkins, Harvard and the University of South Carolina to name a few. Collexis shares of common stock are traded under the symbol CLXS on the OTC Bulletin Board (OTC BB). For more information visit http://www.collexis.com.

This press release contains forward-looking statements. Such statements are valid only as of today, and we disclaim any obligation to update this information. These statements are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made. These statements are based on our current beliefs and expectations as to future outcomes. Factors that could affect future performance include business and economic trends, the ability to continue funding operating losses, fluctuations in operating results, continued success in developing our research software and other risk factors as disclosed in our public filings with the Securities and Exchange Commission.


'/>"/>
SOURCE Collexis
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Scientists plan human cloning clinic in the United States
2. How do patients benefit of clinical trials
3. Magnetic resonance angiography in clinical medicine
4. Clinical trials need to be more frank
5. AEternas acquisition of Zentaris being followed up with its new product pipeline and clinical development strategy
6. Physicians Lack Clinical Guidelines For Treating Elderly With Multiple Illnesses
7. The Growing Rise In Clinical Research Could Lead To A Compromise In Quality Of Research And Ethics
8. Clinical Comparisons Between ADHD Drugs Are Less
9. Specialized Clinics For Manipurs AIDS Patients
10. Outsourcing clinical trials to India
11. Erectile dysfunction: an early warning sign of clinically silent coronary artery disease?
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... June 25, 2016 , ... ... and applications at AcademyHealth’s Annual Research Meeting June 26-28, 2016, at the Hynes ... important health care topics including advance care planning, healthcare costs and patient and ...
(Date:6/25/2016)... ... , ... As a lifelong Southern Californian, Dr. Omkar Marathe earned his Bachelors ... Geffen School of Medicine at UCLA. He trained in Internal Medicine at Scripps Green ... hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had the opportunity to train ...
(Date:6/24/2016)... ... ... Those who have experienced traumatic events may suffer from a complex set of ... or alcohol abuse, as a coping mechanism. To avoid this pain and suffering, Serenity ... event. , Trauma sufferers tend to feel a range of emotions, from depression, guilt, ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... now offering micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has extensive experience with ... Damon brackets , AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation is a ...
(Date:6/24/2016)... ... 24, 2016 , ... The Haute Beauty Network, affiliated with ... as a prominent plastic surgeon and the network’s newest partner. , Dr. ... handsome men, look naturally attractive. Plastic surgery should be invisible.” He stands by ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... -- One of Australia,s successful biotechnology scientists, ... new biotechnology company, Noxopharm Limited [ABN 50 608 966 123] ("Noxopharm"). ... list on the ASX. Noxopharm is a clinic-ready company ... Phase 1 clinical study later this year. ... biggest problems facing cancer patients - the ability of cancers to ...
(Date:6/26/2016)... 2016 Jazz Pharmaceuticals plc (Nasdaq: ... Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended ("HSR"), ... Inc. ("Celator"; Nasdaq: CPXX ) expired effective ... As previously announced on May 31, 2016, ... agreement under which Jazz Pharmaceuticals has commenced a tender ...
(Date:6/26/2016)... Ontario , June 27, 2016  VMS Rehab ... Company,s Board will take whatever measures required to build ... Company,s stock which is currently listed on the OTC ... Wexler, Company Chairman and CEO, "We are seeing an ... difficult to understand, not only by the Company, but ...
Breaking Medicine Technology: